Hot Topics · Cross-industry
Biotech Funding Cycle
Venture and public biotech funding driving instrument and CRO demand.
AI-generated · informational only · not investment advice · verify before relying.
01 · The lede
Intelligence brief
SeventhBiz Intelligence
Refreshed 3h agoBiotech funding has crossed from distressed to structural demand tailwind across the research and clinical instrumentation supply chain. The trailing twelve-month biotech VC funding total of approximately $100 billion (CRL, 10-Q, 2026-11-04) is now translating into visible capital equipment purchasing, reagent volume acceleration, and preclinical study bookings at CRO and instrument vendors after four consecutive quarters of weakness.…
The full brief is part of the subscription
03 · Companies
Companies engaging with this topic
Tracked companies with an on-record signal on Biotech Funding Cycle this cycle.
06 · Evidence
Recent mentions
Preview“The Protein Sciences segment's net sales for the quarter ended September 30, 2026 was $219.7 million, which increased 9% compared to the same respective prior year period.”
Segment Results — Protein Sciences
“trends in biopharma and biotech research improved resulting in very strong growth in our liquid handling business.”
Prepared remarks — Patrick Kaltenbach operating business commentary
“A portion of the demand for our products, and of our expectations for future growth, is attributable to customers generating large-scale single cell and spatial data sets for the purpose of developing AI models of biology, including biopharmaceutical companies”
Part II Item 1A — Risk Factors
Unlock Biotech Funding Cycle
The full intelligence brief, how the language shifted quarter over quarter, the bear case, and every company mention — verbatim and source-cited.